Physician profile
William Grimes
NPI 1639460116
$1,827.41
in general payments reported to CMS, 2019-2025
28 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.94 · 2020: $91.38 · 2021: $15.75 · 2022: $167 · 2023: $288 · 2024: $663 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $287.23 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $187.24 | 2020-2025 | |
| Lilly USA, LLC | $168.59 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $103.24 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Inari Medical, INC. | $103.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $100.94 | 2023-2025 | |
| Novo Nordisk INC | $97.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $75.55 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $73.97 | 2021-2023 | |
| Exact Sciences Corporation | $70.41 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $70.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $70.20 | 2020-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.40 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $44.38 | 2023-2025 | Evenity, Prolia, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.15 | 2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.17 | 2023-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $32.56 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $28.57 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $22.14 | 2022 | |
| Daiichi Sankyo INC. | $22.07 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.42 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.39 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $17.32 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2022 | |
| Harmony Biosciences LLC | $17.02 | 2023 | Wakix |
| Corcept Therapeutics | $16.62 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $15.51 | 2023 | |
| Gilead Sciences, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Grimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.